Trulieve Uplists to NYSE Today — Herbal Dispatch (HERB / LUFFF) Positioned as Prime Medical Cannabis Play for MSO Buyout/Partnership with Strong Canadian Medical Platform + Large Medical Exports

Trulieve just became the first major U.S. cannabis company to uplist to the NYSE (trading as TRLV starting today, June 10). This is a big signal for the sector as federal rescheduling of medical marijuana to Schedule III paves the way for more institutional capital, traditional finance, and cross-border opportunities.

Other MSOs are expected to follow. In this environment, companies with **robust medical cannabis platforms** — especially those with proven domestic insured medical channels and international export capabilities — become highly attractive targets or partners for U.S. players seeking Canadian/world market exposure.

**Herbal Dispatch Inc. (CSE: HERB | OTCQB: LUFFF)** stands out here. They're a cannabis e-commerce and distribution leader with a clear **all-medical focus** in Canada and accelerating medical exports.

# Key Medical Cannabis Highlights:

* **Canadian Medical Platform (HeroDispatch.com):** Dedicated platform for veterans and insured medical patients targeting Canada's \~$245M annual Veterans Affairs Canada (VAC) reimbursement market. Direct-to-consumer medical revenue **up 98% YoY** in Q1 2026. Veteran registrations surged \~400% in early 2026 vs. full 2025. High gross margins (>50% in the veteran/insured channel), direct Blue Cross billing, insurance integration, and clinic partnerships. Focus on high-quality craft products for conditions like PTSD, pain, and anxiety. This is a scalable, recurring, high-margin medical revenue stream.
* **Medical Cannabis Exports:** Since the start of 2026, completed international shipments totaling \~1,321+ kg (over 1.3 metric tonnes) of **medical cannabis**, with recent updates pushing toward \~1.5 tonnes including a record 500kg shipment to Europe, 452kg multi-client Europe, 298kg to Germany, 261-262kg shipments, and inaugural $350k shipment of medical gummies to Australia. Backed by Export Development Canada (EDC) financing. EU-GMP compliant and focused on regulated medical markets.

By emphasizing medical channels domestically and medical exports internationally, Herbal Dispatch is well-aligned with the global push for legitimate medical cannabis post-Schedule III. Low market cap + real traction makes them a compelling candidate for acquisition or strategic partnership by a big U.S. MSO looking to expand into Canada and beyond.

Not financial advice, But the setup looks timely as the industry shifts toward more professional, medical-focused growth.

thoughts on potential MSO interest?

https://preview.redd.it/oa2gvo1zrg6h1.png?width=1200&format=png&auto=webp&s=1ed833b04d09bf3f5fbf9abd75a0d3b01a3060d4

[https://www.newsfilecorp.com/release/300675](https://api.newsfilecorp.com/redirect/Lq1m1iDYjV)

https://preview.redd.it/1fm7r9snsg6h1.png?width=550&format=png&auto=webp&s=f12861782333a85587c625940437be5d4d8e5bb4